Haematopoietic stem cell transplantation (HSCT) is a potentially curative treatment option for patients with haematological malignancies (such as leukaemia, lymphoma, myeloma and myelodysplasia) and nonmalignant diseases (such as haemoglobinopathies, aplastic anaemia and immune deficiency syndromes) 1 . In the USA, >8,000 patients received allogeneic HSCT in 2013 (REF. 1). Before HSCT, patients commonly undergo conditioning therapy, which comprises treatment with preparative chemotherapy to eradicate diseased haemato logical cells, provide an immunosuppressed environment for donor cell engraftment and prevent the rejection of haematopoietic progenitor cells from the donor, which are subsequently infused 1 . In autologous HSCT, donor cells are obtained from the patient, frozen and infused after conditioning chemotherapy 2 . In allogeneic HSCT, donor cells are derived from a healthy donor with varying degrees of HLA matching with respect to the recipient 2 . Haematopoietic stem cells are most commonly obtained from the bone marrow, peripheral blood or umbilical cord blood 1 .
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The period between conditioning therapy and donor cell engraftment is typically 10-12 days and is marked by profound neutropenia, particularly in the setting of myeloablative conditioning 3 . Graft-versus-host disease (GVHD) occurs when allo reactive T cells from the donor attack healthy tissues in the recipient and arises almost exclusively in patients who have undergone allogeneic HSCT 3 . Following allogeneic HSCT, functional reconstitution of the immune system occurs gradually over several months, during which time immunosuppressive prophy laxis of GVHD is gradually tapered if GVHD does not develop 4 . Patient outcomes and survival after HSCT depend upon the underlying disease as well as individ ual patient factors 4 . The two most common underlying causes of death after allogeneic HSCT are disease relapse and GVHD 5 . The NIH criteria subcategorize GVHD into classic acute GVHD, which has defining features and occurs within 100 days after transplantation; persistent, recurrent or late acute GVHD, which presents with the Abstract | Haematopoietic stem cell transplantation (HSCT) is central to the management of many haematological disorders. A frequent complication of HSCT is acute graft-versus-host disease (GVHD), a condition in which immune cells from the donor attack healthy recipient tissues. The gastrointestinal system is among the most common sites affected by acute GVHD, and severe manifestations of acute GVHD of the gut portends a poor prognosis in patients after HSCT. Acute GVHD of the gastrointestinal tract presents both diagnostic and therapeutic challenges. Although the clinical manifestations are nonspecific and overlap with those of infection and drug toxicity, diagnosis is ultimately based on clinical criteria. As reliable serum biomarkers have not yet been validated outside of clinical trials, endoscopic and histopathological evaluation continue to be utilized in diagnosis. Once a diagnosis of gastrointestinal acute GVHD is established, therapy with systemic corticosteroids is typically initiated, and non-responders can be treated with a wide range of second-line therapies. In addition to treating the underlying disease, the management of complications including profuse diarrhoea, severe malnutrition and gastrointestinal bleeding is paramount. In this Review, we discuss strategies for the diagnosis and management of acute GVHD of the gastrointestinal tract as they pertain to the practising gastroenterologist.
Allogeneic HSCT
Transplantation in which a patient receives haematopoietic stem cells from a genetically similar, but not identical, donor.
Autologous HSCT
Transplantation in which a patient's haematopoietic stem cells are harvested, stored for the duration of the patient's conditioning regimen, and later returned to that same patient for re-engraftment.
Myeloablative conditioning
The complete or near complete depletion of native bone marrow cells via the administration of cytotoxic chemotherapy such as cyclophosphamide, often along with radiation therapy.
features of acute disease but occurs more than 100 days after transplantation; classic chronic GVHD, which can occur at any time after transplantation, has defining characteristics and lacks the features of acute disease; and an overlap syndrome, which includes features of both chronic and acute GVHD 6, 7 . The incidence of acute GVHD varies with respect to several clinical variables, with cumulative incidence rates ranging from 40-80% of HSCT recipients 8 . Risk factors for acute GVHD include differences in histo compatibility between donor and recipient, patient age, source of donor cells, conditioning and prophylaxis regimens used and graft manipulation techniques 9 . The most common tissues affected by acute GVHD are the skin, liver and gastrointestinal tract. Gastrointestinal acute GVHD is the most difficult of these conditions to treat and is the greatest cause of GVHD-related mortality 9 . Although reports vary, the cumulative incidence of gastrointestinal acute GVHD might be as high as 60% (REF. 8) . Although hepatic manifestations are relatively less common than skin and gastrointestinal conditions, gastroenterologists might be tasked with their management, for which we refer the reader to a review of the hepatobiliary manifestations of GVHD 10 . In this Review, we focus our discussion on the gastro intestinal manifestations of acute GVHD, as this condition is often the most severe and therefore poses substantial diagnostic and therapeutic challenges. For an overview of chronic GVHD and its management, we refer the reader to two review articles 9, 11 . We discuss the aspects of gastrointestinal acute GVHD that are most pertinent to the practising gastroenterologist, including pathophysiology, endoscopic characteristics, diagnosis, risk stratification, treatment, management of complications and supportive care. Importantly, we pay special attention to the latest paradigm-shifting developments in the study of gastrointestinal acute GVHD, including the role of gut dysbiosis in pathogenesis, data regarding endoscopic diagnosis, the search for novel biomarkers and changes in staging and risk stratification.
Pathophysiology
The pathophysiology of acute GVHD is incompletely understood. Donor T cell responses and inflammatory cytokines are the most studied immune components that mediate tissue damage. Downregulation or inhibition of the recipient regulatory T (T reg ) cell response and upregu lation of the recipient effector T cell response, which is possibly exacerbated by treatment with immunosuppressive regimens, contributes to the lack of tolerance of allogeneic donor cells to recipient tissues 12 . Dysfunction in recipient antigen-presenting cells also influences immune activation in acute GVHD 12 . In the gut, emerging evidence suggests that the immune dysregulation observed in acute GVHD leads to further perturbation of the intestinal epithelium, specifically intestinal stem cells, Paneth cells and goblet cells 13 . Imbalances in the gut microbiota are also likely to have an important role in the development of acute GVHD of the gastrointestinal tract; conditioning regimens, broad-spectrum antibiotics, immuno suppressants and the introduction of foreign lymphocytes from the donor profoundly alter the composition of the gut microbiota [14] [15] [16] . The degree of microbial imbalance has been shown to correlate with long-term outcomes and transplant-related mortality in gastrointestinal acute GVHD 15 . Moreover, Clostridium difficile has been implicated as a potential trigger of immune dysregulation that might contribute to the development of acute GVHD via local immune activation 17 . As the complex interplay between the immune system and the gut microbiota is further elucidated, the intestinal bacteria might become novel therapeutic targets in the management of gastrointestinal acute GVHD. Gut dysbiosis has been observed in both acute GVHD and IBD 18, 19 . Moreover, acute GVHD and IBD share clinical, histopathological and genetic features 20, 21 . For example, polymorphisms in NOD2, which encodes the intracellular bacterial sensor nucleotide-binding oligomerization domain-containing protein 2 (NOD2), are associated with IBD and might also be linked with acute GVHD development in candidate gene studies 20, 21 ; however, the latter observation remains to be fully validated.
A striking consequence of the immune dysregulation observed in acute GVHD is a multifactorial disturbance of the gut mucosal barrier, which manifests with severe secretory diarrhoea 22 . The immune-mediated destruction of the intestinal mucosa leads to a failure of fluid resorption, particularly in the ileum, and is largely responsible for voluminous diarrhoea in patients with acute GVHD 22, 23 . In addition, the destruction of mucosal cells at the brush border and consequent reduction in luminal levels of disaccharidase enzymes creates an osmotic effect due to the passage of unabsorbed carbohydrates 22, 23 . Dysbiosis depletes the gut of bacterial populations, which might otherwise mitigate this effect via metabolism of these luminal polysaccharides 23 . Furthermore, compromise of brush border tight junctions (also known as zonulae occludentes) in the setting of a vigorous inflammatory response can lead to substantial mucosal protein loss, therefore drawing fluid into the intestinal lumen via oncotic pressure 24 .
Key points
• Acute graft-versus-host disease (GVHD) of the gastrointestinal tract is a common complication in patients after haematopoietic stem cell transplantation (HSCT) that results in considerable morbidity and mortality • As the clinical, serological and radiographical findings in gastrointestinal acute GVHD are nonspecific, a broad differential diagnosis should be considered, particularly potential infectious causes and chemotherapeutic or immunosuppressant toxicity • Expedient endoscopy and histopathology are helpful in excluding possible conditions that mimic gastrointestinal acute GVHD; nevertheless, the diagnosis is ultimately based on clinical criteria • Several novel diagnostic, prognostic, risk and predictive biomarkers have been identified for gastrointestinal acute GVHD; however, none have yet been integrated into routine clinical practice • Upon diagnosis of gastrointestinal acute GVHD, timely first-line therapy with systemic corticosteroids (such as prednisone or methylprednisolone) and/or oral non-absorbable corticosteroids (such as beclomethasone or budesonide) is crucial • Acute GVHD leads to substantial gastrointestinal symptom burden, including profuse diarrhoea, abdominal pain, severe malnutrition and gastrointestinal bleeding; providing supportive and palliative care is a critical role of the gastroenterologist
Moreover, inflammatory-cell-mediated destruction of apical bile salt transporters in the ileal brush border leads to bile acid malabsorption and might lead to bile salt diarrhoea 25 . Finally, a number of the agents that are used to prevent and treat acute GVHD and its complications are themselves cathartic agents, most notably the motilin agonist tacrolimus, mycophenolate mofetil (MMF) and magnesium salts 25 . In some instances, these agents might contribute to the voluminous diarrhoea that is frequently observed in acute GVHD.
Diagnosis
As discussed in this section, serological markers, radiology and endoscopy all have roles in the evaluation of patients with suspected acute GVHD of the gastrointestinal tract. Although these tools help to confirm the diagnosis or screen for alternative or coexisting pathologies, the diagnosis of acute GVHD ultimately depends on classic clinical features and the exclusion of alternative diagnoses 26 .
Signs and symptoms. Acute GVHD can affect any segment of the gastrointestinal tract and manifest with nonspecific symptoms. In the oropharynx, mucositis -which is characterized by oral pain, odynophagia, anorexia, blistering, aphthae and gingivitis -might be a manifestation of either acute GVHD or the result of myeloablative conditioning therapy 27, 28 . Conditioning regimens are the predominant cause of mucositis in the initial 2-3 weeks after HSCT, with acute GVHD becoming a common culprit thereafter 28 . Severe oral and oesophageal involvement might lead to bleeding, superinfection and, rarely, airway obstruction 29 . Although isolated acute GVHD of the oesophagus is rare, it might present with odynophagia, dysphagia or chest pain 30, 31 . The earliest manifestations of gastroduodenal acute GVHD can be insidious and include loss of appetite, early satiety, dyspepsia and weight loss [32] [33] [34] . Recognizing these symptoms might offer the best chance for early intervention, which could potentially alter the clinical course of the disease. Symptoms might progress to severe nausea, incessant vomiting, epigastric pain and upper gastrointestinal bleeding [32] [33] [34] . Importantly, before engraftment, chemotherapy-induced toxicity and opportunistic infections can cause gastrointestinal manifesta tions similar to those of acute GVHD. In addition, it is not uncommon for drug toxicity, acute GVHD and infections to coexist 35 . Acute GVHD of the lower gastrointestinal tract, which affects both the small and large intestine, manifests with abdominal pain and diarrhoea 36 . The occurrence of diarrhoea 2 weeks after HSCT is the most common presenting symptom of lower gastrointestinal acute GVHD; however, notably, diarrhoea can develop at any time after engraftment occurs independently of oral intake and can be profound and incessant, with up to several litres of output per day 36 . Although initially watery, the stool might turn mucoid owing to loss of transmucosal proteins and might be bloody in the setting of mucosal denudation 37 . Moreover, small intestinal mucosal injury and protein loss due to acute GVHD can lead to malabsorption and malnutrition 38 . Paradoxically, severe disease can lead to paralytic ileus, either spontaneously or as a result of analgesic and anti-motility agents such as morphine, loperamide or diphenoxylate 36 . The incidence of severe gastrointestinal bleeding after HSCT has markedly declined owing to improvements in fungal, antiviral and acute GVHD prophylaxis. The cumulative incidence of gastrointestinal bleeding of any severity has been reported as 9%, and as 2% for severe gastrointestinal bleeding 37, 39 . Although patients who have received HSCT can certainly present with causes of gastrointestinal bleeding that are not related to the transplantation (such as oesophagitis, peptic ulcer disease, angiodysplasia, diverticulosis and haemorrhoids), acute GVHD remains the most common aetiological factor 40 . Predisposing factors to gastrointestinal bleeding in acute GVHD include prolonged thrombocytopenia, an advanced stage of acute GVHD, the presence of thrombotic microangiopathy and secondary infection 39 . Importantly, severe gastrointestinal bleeding in acute GVHD is an independent predictor of mortality, with mortality approaching 40% (REF. 37 ).
Imaging findings. Imaging findings in acute GVHD are nonspecific and of limited clinical utility. Nonetheless, CT scan with intravenous and oral contrast reveals abnormal mucosal enhancement of thickened bowel segments in the majority of patients with acute GVHD 41, 42 . The distribution of bowel wall thickening in acute GVHD can be patchy or diffuse. Of note, small intestinal involvement is present in ~75% of cases, which aids in the exclusion of pathologies such as C. difficile colitis 41, 42 . Focal thickening of the ileum and right colon wall might suggest typhlitis (also known as neutropenic enterocolitis) 42 . The degree of bowel wall thickening in acute GVHD is typically moderate, while severe thickening is more commonly observed in patients with a coexisting infection or typhlitis 41 . In rare circumstances, CT scan might also reveal pneumatosis intestinalis (intramural bowel gas) with multiple thin-walled, air-filled pockets in the colonic submucosa or subserosa 43 . Magnetic resonance enterography (MRE) represents an alternative method for assessing gastrointestinal GVHD, and findings are similar to those obtained using CT scan 44 .
In addition, contrast-enhanced ultrasono graphy (CEUS) and PET-CT are non-invasive modalities that are currently being investigated for the assessment of gastrointestinal tract involvement in GVHD 45, 46 .
Biomarkers. The search is underway for effective biomarkers that anticipate a patient's risk of developing acute GVHD, diagnose the disease at its earliest stages, estimate the prognosis and predict response to treatment. Several promising biomarkers have been identified, although none have yet been validated to guide diagnosis or treatment. Of the inflammatory bio markers that are elevated in GVHD, those with the greatest relevance to GVHD of the gastrointestinal tract are suppression of tumorigenicity 2 (ST2; also known as IL-1RL1, T1 and IL-33R), regenerating islet-derived protein 3α (REG3α), TNF receptor 1 (TNFR1) and T cell immunoglobulin and mucin domain-containing protein 3 (TIM3; also known as HAVcr-2). The two most informative biomarkers for acute GVHD are ST2 and REG3α. ST2 is shed from activated T cells and might function as a decoy receptor for IL-33, therefore inhibiting the IL-33-dependent induction of a pro-inflammatory phenotype in T cells 47 . REG3α is secreted primarily by Paneth cells and functions as an antimicrobial peptide and regulator of Gram-positive bacteria in the gut 47 . A large study (n = 1,287) that utilized a two-biomarker signature measuring ST2 and REG3α concentrations in the blood 1 week after HSCT identified patients who were at high risk of developing lethal GVHD (~20%) and reported a cumulative incidence of 6-month non-relapse mortality (NRM) of 28% in the high-risk group compared with 7% in the low-risk group (P < 0.001) 48 . Compared with the low-risk group, highrisk patients had a significantly greater GVHD-related mortality (4% versus 18%, P <0.001) and risk of severe gastrointestinal acute GVHD (8% versus 17%, P <0.001). The Ann Arbor (AA) scoring system, which originally combined the plasma concentrations of three biomarkers (TNFR1, REG3α and ST2) to define three distinct risk groups at the symptomatic onset of acute GVHD, can also now be defined successfully by only two biomarkers, REG3α and ST2 (REF. 49 ). The AA scores identify patients who will later develop acute GVHD of the lower gastrointestinal tract but who present with only a rash. Patients who present with only skin involvement at the time of diagnosis are classified as AA3 (high risk) by their biomarker profiles and are twice as likely to develop gastrointestinal acute GVHD compared with patients who are classified as AA1 (low risk) 49 . The two-biomarker AA algorithm is superior to the three-biomarker algorithm, as it can accurately identify more patients who are at low risk, which is perhaps a result of the adoption of a commercial enzyme-linked immunosorbent assay (ELISA) that has increased sensitivity for detection of ST2, the best single biomarker, compared with that used when the initial three-biomarker AA algorithm was developed 48 . Although promising, this algorithm is currently best used in the context of a clinical trial, as it has not yet been demonstrated that a therapeutic intervention based on the biomarker risk can change long-term outcomes. Further refinements, including an increase in the positive predictive value (perhaps through serial monitoring) will be required before the widespread adoption of biomarkers to guide clinical practice. Of the two other serum biomarkers for gastrointestinal GVHD, levels of TNFR1 (a membrane receptor for TNF that is cleaved into a soluble form after ligand binding) also strongly correlates with the overall severity of acute GVHD, response to treatment, NRM and survival 50, 51 . In smaller studies, high serum concentrations of TIM3, an activation marker on CD4 + T cells that regu lates macrophage function, have been shown to predict the development of severe GVHD, and high levels of ST2 and TIM3 have been correlated with 2-year NRM and overall survival in patients with GVHD 52, 53 . In addition, numerous inflammatory markers (such as erythrocyte sedimentation rate and C-reactive protein (CRP) levels), angiogenic markers (such as follistatin and angiopoietin 2) and microbiota-derived metabolites (such as butyrate) are under active investigation as biomarkers; however, these markers are nonspecific to gastrointestinal acute GVHD [54] [55] [56] . In small studies, faecal calprotectin levels were demonstrated to have potential as a diagnostic tool 57, 58 . Citrulline levels have also been shown to correlate with enterocyte damage 59 . Finally, serum albumin levels might be a potential prognostic biomarker, possibly as a surrogate for the degree of protein-losing enteropathy or for nutritional status 22, 24, 60 .
Endoscopic findings. Endoscopic findings in acute GVHD vary broadly, which reflects the phases of progressive mucosal inflammation, including normal mucosa, mucosal oedema, mild erythema, mucosal erosions, superficial ulcerations, severe mucosal sloughing and mucosal denudation 61, 62 (FIG. 1) . Studies using the magnification endoscopy with water immersion technique have demonstrated the presence of short, blunted villi in the mucosa of the duodenum and ileum and mucosal oedema, erosion, and 'tortoiseshell-like' mucosa in the colon 63 . The most commonly used system for the classification of endoscopic findings in acute GVHD is the Freiburg Criteria 64 (TABLE 1) . However, the diagnostic reliability of endoscopic findings is unclear; studies have reported diagnostic sensitivities and specificities of 34-89% and 65-79%, respectively, when compared with histological diagnosis [64] [65] [66] . In addition, some studies have shown that the concordance between the macroscopic and histological findings in acute GVHD are as low as 38.9% and that a difference of two grades or more is observed in 28% of cases [64] [65] [66] [67] . Accordingly, mucosal biopsy is necessary for a reliable diagnosis, and both endoscopically normal and abnormal mucosa should be sampled 68, 69 . It is worth reiterating that although the diagnosis of acute GVHD should be confirmed with biopsy of the affected organ or tissue when possible, the diagnosis is ultimately made on the basis of clinical findings. In addition, biopsies should not delay the management of the disease in patients who have classical clinical features of acute GVHD 26, 70 . Oesophagogastroduodenoscopy (EGD) and colonoscopy are both appropriate diagnostic approaches and can be chosen based on the patient's most prominent symptoms. One study reported diagnostic accuracies of 67-80% for EGD, 58-80% for sigmoidoscopy, 83-87% for colonoscopy, 87-100% for ileocolonoscopy and 92-93% for EGD with sigmoidoscopy 64 . However, several studies have reported that biopsies from the distal colon yield the highest sensitivities for detecting acute GVHD, ranging from 82% to 95% (REFS 67, 71) . It has also been demonstrated that very few diagnoses of isolated upper gastrointestinal acute GVHD would be missed by performing lower endoscopy alone 72 . Thus, owing to its diagnostic yield, safety and the non-requirement for sedation, flexible sigmoidoscopy with biopsy might be considered the initial endoscopic test of choice 73, 74 . Notably, such an approach might not detect superimposed cytomegalovirus infection, which might be scattered throughout the bowel or localized to the ascending colon 75 . In our clinical practice, we generally do not use purgatives in patients who have received HSCT and who are undergoing lower endoscopy; the volume of diarrhoea in this patient popu lation usually allows for adequate inspection of the mucosa without the need for additional bowel cleansers. Importantly, newer data suggest that upper and lower endoscopy have similar diagnostic yields, even in patients who present with diarrhoea 76, 77 . If EGD is performed in such patients, duodenal biopsies have a diagnostic yield higher than other sites of the upper gastrointestinal tract 78 . However, the endoscopist must be aware of the risk of biopsy-induced duodenal haematoma 79 .
Box 1 | Proposed endoscopic approach in suspected acute GVHD
Numerous variables must be taken into account when considering an endoscopic evaluation in a patient following haematopoietic stem cell transplantation (HSCT). This box summarizes our recommendations for the pre-procedural and post-procedural considerations. It also provides our proposed endoscopic approach in patients after HCST who are being evaluated for gastrointestinal acute graft-versus-host disease (GVHD). Owing to the often patchy or diffuse distribution of endoscopic findings in acute GVHD in the gastrointestinal tract, a common pitfall in diagnosis is the failure to obtain biopsy samples from multiple sites. The American Society of Gastrointestinal Endoscopy (ASGE) suggests two potential approaches in patients with suspected GVHD 80 . The first is to obtain four biopsy samples from the rectosigmoid and the descending colon. If this method is non-diagnostic, an EGD with four biopsy samples from the gastric antrum, gastric body, duodenum and distal oesophagus is recom mended. An alternative approach is to perform ileo colonoscopy to obtain four biopsy samples from each anatomic segment of the colon 80 . Our recommendation
Pre-endoscopy
2) in patients with diarrhoea and suspected acute GVHD is to perform lower endoscopy (advancing the scope as far proximally as can be safely performed), taking biopsy samples from each colonic segment and any discrete lesions. We perform EGD with biopsies from each anatomic segment in patients with a negative finding on colonoscopy and symptoms consistent with upper gastrointestinal involvement (such as dyspepsia, nausea, vomiting, epigastric pain or upper gastro intestinal bleeding). We recommend that biopsy specimens from different locations be placed in separate containers with 10% buffered formalin to enable disease localiza tion. As with routine endoscopic biopsies, specimen orientation by the gastroenterologist is not required 80 .
The precise site of endoscopic biopsy is also important. In general, we recommend that biopsy of areas of sloughed mucosa should be avoided, as they are less likely to be diagnostic. In addition, biopsy of frankly ulcerated areas might be difficult for the pathologist to interpret, as they contain necrotic cells that lack specific histological features. In the stomach, there is evidence that the use of PPIs might artificially increase the number of apoptotic bodies in the antrum, but not in the fundus, which might obscure the histopathological diagnosis of acute GVHD. Thus, the acquisition of fundic biopsies should be considered in patients receiving treatment with PPIs 81 . If discrete ulcers are identified during endoscopy and superimposed cytomegalovirus infection is suspected, biopsies of the ulcer base are essential owing to the cytopathic effect of cytomegalovirus in endothelial cells, ganglion cells and other mesenchymal cells 82 . Adequate tissue sampling is again vital, as studies have demonstrated that the sensitivity of performing three, six and ten biopsies is 80%, 90% and 99%, respectively 82 . Endoscopic features of herpes simplex virus (HSV) infection in the oesophagus include vesiculation and ulceration 83 . These ulcers tend to be multiple, well circumscribed, uniform and smaller than those observed during cytomegalo virus infection. Although HSV colitis is rare, it can mimic the endoscopic features of acute GVHD, cytomegalovirus or other forms of colitis. Endoscopic findings in HSV colitis might include mucosal oedema, erythema and well-demarcated ulcers of variable size and depth, with or without purulent exudate, that are often separated by normal-appearing mucosa 84 . HSV infection is more likely to be detected by sampling the edge of an ulcer, as HSV infects squamous epithelial cells 83 . Biopsy material for viral culture can be stored in containers with viral transport medium, and PCR can be used to test for the presence of viral pathogens 85 .
In patients with acute GVHD who fail to respond to first-line treatment, repeat endoscopy might be needed to re-evaluate the stage of disease, assess response to therapy and exclude alternative or superimposed diagnoses. In one study, approximately one-quarter of patients who were unresponsive to first-line acute GVHD treatment were found to have cytomegalovirus infection following repeat endoscopy 86 . A second study reported that 71% of patients with ongoing symptoms had histological findings on repeat endoscopy that differed from those of the initial endoscopic procedure, which led to changes in therapy in 77% of such patients with ongoing symptoms 87 . Figure 2 | Recommended diagnostic algorithm for patients with suspected gastrointestinal acute GVHD after HSCT. Post-haematopoietic stem cell transplantation (HSCT) patients who develop gastrointestinal symptoms must be carefully evaluated. The initial step is to review medications that might cause gastrointestinal adverse effects, assess for acute infection and rule out non-transplantrelated gastrointestinal illness. If these aetiologies are excluded, graft-versus-host disease (GVHD) must be considered as a potential aetiology. If there is a high suspicion for gastrointestinal acute GVHD, empirical treatment can be initiated as the diagnostic work-up is undertaken. If there is a moderate or low suspicion for gastrointestinal acute GVHD, an endoscopic evaluation should be undertaken in accordance with the patient's predominant symptoms (upper or lower gastrointestinal). Once a diagnosis is established, treatment should be promptly initiated. If the initial study is non-diagnostic but gastrointestinal acute GVHD is still a concern, further endoscopic evaluation should be undertaken. Once a diagnosis is established, appropriate therapy must be initiated. First-line therapy for GVHD typically includes corticosteroids. Non-diagnostic Non-diagnostic Persistent concern for acute GVHD?
Small bowel capsule endoscopy
A procedure in which a capsule containing a wireless camera is ingested by a patient and used to visualize areas of the small bowel that are difficult to access using conventional endoscopy.
Endoscopy with mucosal biopsy is generally safe in patients with acute GVHD. However, bleeding from biopsy sites and intra-mucosal haematomas in the setting of thrombocytopenia have been reported 79 . In a systematic review of the safety of endoscopic procedures in patients with thrombocytopenia (not exclusively with GVHD), the overall bleeding rate was found to be 1.9-2.9% (REF. 88 ). According to the ASGE guidelines, a platelet count >50 × 10 9 /L is recommended before endoscopy with biopsy, and a count >20 × 10 9 /L is recom mended for diagnostic endoscopy 89, 90 . Although data are lacking, frank perforation due to endoscopic biopsy is rare 91 . Finally, although patients with neutropenia after HSCT are at a higher risk of clinically relevant bacter aemia, there are insufficient data in the liter ature to support or oppose the use of prophylactic antibiotics before endo scopy with biopsies in patients with absolute neutrophil counts <500 cells/μl ( equivalent to >0.5 × 10 9 /L) 92 . Small bowel capsule endoscopy has also been evaluated as a diagnostic tool in acute GVHD. The disease distrib ution identified by capsule endoscopy ranges from scattered lesions to contiguous enteritis 93 . Findings include normal mucosa, diffuse erythema, mucosal oedema, erosions and ulceration 93 . In one small trial that involved a cohort of 13 patients, capsule endo scopy showed high sensitivity (100%) and negative predictive value for diagnosis of acute GVHD 94 . Another study suggested that capsule endoscopy can serve as a diagnostic modality that spares the need for EGD in patients who have a high likelihood of small bowel acute GVHD and a high risk of complications from endo scopy 95 . Nevertheless, we recommend against using capsule endoscopy owing to the lack of specificity for acute GVHD compared with conventional endoscopy, the inability to obtain tissue biopsy samples and the potential risk of capsule retention in patients with diffuse enteritis. Another emerging modality is confocal laser endomicroscopy (CLE), which enables in vivo histological assessment to be performed during endoscopy, therefore obviating the need for biopsy. Several small studies have shown that CLE has excellent sensitivity and specificity for the diagnosis of acute GVHD 96, 97 .
Histopathological findings.
The most common histological finding in acute GVHD is epithelial cell apoptosis; as intestinal stem cells are targets of the disease, the most prominent histological manifestation is apoptotic bodies in the regenerative compartment of the crypt 98, 99 . Crypt dropout (effacement of the crypt epithelium) is more widespread in high-grade disease and involves dropout of individual crypt cells in low-grade specimens (grade 2) and entire crypts or multiple contiguous crypts in high-grade specimens (grade 3) 100 (FIG. 3) .
The highest-grade histopathology (grade 4) demonstrates mucosal sloughing and loss of the epithelium 101 . In addition, the number of Paneth cells -which are primarily located next to stem cells in small intestinal crypts -inversely correlates with the risk of mortality in acute GVHD 102 . Accordingly, the quantification of Paneth cells on duodenal biopsy might aid in establishing the diagnosis and in prognosticating disease severity. Although high-grade histopathology, particularly grade 4, is specific for acute GVHD, it might be difficult to distinguish low-grade acute GVHD from alternative diagnoses such as medication toxicity 103 . The most commonly used histological classification for acute GVHD is a four-tiered grading system 104 (TABLE 2). Grade 1 histology is identified in 90% of patients with acute GVHD, grade 2 histology in 2%, and grades 3 or 4 in 30% combined 104 . Importantly, a single pathological specimen might contain focal areas of varying grade, making definitive grading difficult and probably introducing some element of subjectivity to the final pathological grade assignment in these instances. However, despite well-defined grading schema, histo logical grade has not been shown to correlate with clinical manifestations of disease 105 . In addition, with the exception of grade 4 histology, which portends a poor prognosis, histological grade is not predictive of treatment response, morbidity or mortality 36, 105 . More so, because of the patchy, diffuse distribution of GVHD, the absence of histological findings should not preclude treatment in the appropriate clinical setting. 
Staging and prognosis
Several clinical staging systems have been proposed to classify the severity of acute GVHD. Historically, these have included the Glucksberg and the International Bone Marrow Transplant Registry (IBMTR) grading systems 106 . Both systems were updated by Przepiorka et al. 107 to include skin, liver and both upper and lower gastrointestinal involvement
. Grading is based solely on clinical features, and endoscopic, histological and radiological findings are not taken into account. Note that patients might be classified with high-grade acute GVHD if skin or liver stage is advanced, despite having either absent or minimal-stage gastrointestinal involvement.
Overall, the clinical stage and grade of acute GVHD correlates with treatment response and mortality, with high scores being associated with poor patient outcomes 36, 108 . In a large retrospective cohort study in patients who received an allogeneic HSCT for chronic myeloid leukaemia, the transplant-related mortality for grades 0-IV acute GVHD was 28%, 27%, 43%, 68% and 92%, respectively 109 . Another study demonstrated a relative risk of acute GVHD-related mortality of 2.28 for grades III-IV compared with grade II disease 110 . In 2015, MacMillan and colleagues 111 proposed a novel risk score for acute GVHD that used multiple regression analysis to stratify patients into standard-risk and high-risk groups. By use of this model, high-risk patients were shown to be much less likely to respond to initial corticosteroid therapy and had at least a twofold increased risk of mortality. The authors proposed that patients who were deemed high risk should be considered for more intensive first-line therapy than corticosteroids alone.
There are several important limitations to the current grading schemas for acute GVHD. First, the systems are not based on data from validated clinical trials. Second, they do not take into account the dynamic nature of the disease and usually reflect only maximal disease severity. Finally, they are calculated retrospectively and thus cannot be used as a prognostic tool. Some investi gators have proposed that a scoring system based on an area under a receiver operating characteristic (ROC) curve model of disease activity might better reflect disease activity and enable more accurate prognostication of NRM 112 . In addition to standardized staging, clinical features have been used to predict outcomes in acute GVHD. Severe gastrointestinal bleeding, hypoalbuminaemia and serum biomarker levels (including ST2, REG3α, TNFR1 and TIM3) are associated with increased mortality in acute GVHD 37, 60 . A study demonstrated that a composite of clinical features -including jaundice, age >18 years, lack of response to corticosteroids and gastrointestinal bleeding -correlated with poor outcomes in patients with acute GVHD 113 . Another composite score that included timing of onset, disease severity at diagnosis and visceral organ involvement was reported to be associated with poor survival 110 . By use of radiography, the presence of diffuse small bowel thickening and of pneumatosis intestinalis portended a poor prognosis in patients with acute GVHD 43, 114 .
Differential diagnosis
Given the nonspecific presentation of acute GVHD, a broad differential diagnosis should be considered when evaluating patients with gastrointestinal complaints follow ing HSCT (TABLE 3) . The timing of symptom onset is a key consideration; conditioning therapy is the most common cause of gastrointestinal symptoms in the period immediately following HSCT and is the most likely cause of diarrhoea during the first 3 weeks. Thereafter, acute GVHD becomes more common 36 . After engraftment, it is not unusual for both acute GVHD and conditioning therapy-induced gastrointestinal symptoms to coexist or for one to transition into the other. Diarrhoea secondary to conditioning regimens is typically self-limited and less severe than in acute GVHD 91 . In addition to myeloablative conditioning regimens, ongoing immunosuppressive prophylaxis can cause adverse gastrointestinal effects. Mycophenolate acid (MPA), an inhibitor of purine synthesis in lymphocytes, can cause a colitis that is difficult to distinguish from acute GVHD 115 . MPA is available in two formulations: the prodrug MMF and the sodium salt, enteric-coated mycophenolate sodium (EC-MPS) 116 . Gastrointestinal symptoms occur in nearly half of patients who receive MMF therapy 115 . The most frequent complaint with MMF is watery, voluminous diarrhoea that starts 2-4 weeks follow ing initiation of therapy 115 . Findings on endoscopy range from normal mucosa to ulcer ation and mucosal sloughing. Notably, rectal sparing is observed almost universally in MMF-induced colitis 115 . Moreover, the histology of MMF-induced colitis closely resembles that of acute GVHD; however, eosinophilia and the absence of apoptotic micro-abscesses are more common in MMF-induced colitis 117 . Initial treatment of MMF-induced colitis consists of dose reduction or discontinuation of the medication. Alternatively, some centres utilize EC-MPS, which might improve gastrointestinal tolerability compared with the standard formulation MMF 116 . Infections account for 10-15% of cases of diarrhoea in the period following HSCT 36, 118 , and enteric viral infections are more common than bacterial infections in this setting 119 . Gastrointestinal cytomegalovirus infection should be considered in all patients who receive HSCT (FIG. 4) . Cytomegalovirus infection can present as diarrhoea, abdominal pain, odynophagia or fever occurring weeks to months after HSCT 86 . Diarrhoea is bloody in half of such cases 120 . Similar to acute GVHD, lesions might be found endoscopically anywhere along the gastrointestinal tract with prominent mucositis, mucosal ulceration and sloughing 86 . As patients with 121 . Timely diagnosis and therapy are crucial, as cytomegalovirus infection is an independent predictor of mortality in patients who receive HSCT 86, 122 . In addition, varicella zoster virus (VZV) is another possible viral pathogen that might confound the diagnosis of acute GVHD, whereby disseminated VZV infection presents with abdominal pain, diarrhoea and transaminitis that might precede dermatological manifestations 121 .
A number of non-culturable viruses can cause severe diarrhoea in post-HSCT patients 123, 124 . These viruses, including adenovirus, astrovirus, rotavirus and norovirus, predominate during the winter, are often health care-associated and might cause severe and prolonged illness following HSCT 123, 124 . Upon infection with these viruses, severe diarrhoea might develop with or without upper gastrointestinal symptoms. Viral gastroenteritis and acute GVHD can sometimes coexist, and viral gastroenteritis might be predisposing to or worsen the symptoms of acute GVHD 124 . A growing number of reports suggest that norovirus infection can result in severe, and occasionally life-threatening, complications in patients who are immunocompromised 125 . Norovirus is highly transmissible, and outbreaks can spread rapidly within health care centres. PCR-based testing of stool samples is the standard confirmatory test in suspected cases of norovirus gastroenteritis. Endoscopic findings are variable and might include normal mucosa or severe erythema. Histological assessment might demonstrate villous blunting and prominent cytotoxic lymphocytosis 125 . Among bacterial pathogens, C. difficile is perhaps the most common and most worrisome. The incidence of C. difficile infection among patients who receive allogeneic HSCT ranges from 12 to 27% and is associated with increased mortality 17, 126, 127 . Predisposing factors to C. difficile infection include age >60 years, allogeneic HSCT, chemotherapy before conditioning therapy, severe acute GVHD, use of broad-spectrum antimicrobials and prior vancomycin-resistant enterococci colonization Clinically, C. difficile infection can be indistinguishable from acute GVHD 36, 128 . Endoscopically, pseudomembranes are typically absent in C. difficile-infected immuno suppressed patients, making C. difficile infection more difficult to endoscopically distinguish from acute GVHD 129 . Various treatment guidelines recommend antibiotic therapy with oral metronidazole for mild to moderate cases of C. difficile infection, and oral vancomycin for severe cases 130 . Notably, these guidelines rely on severity scores that utilize white blood cell count, serum creatinine concentrations and serum albumin levels, which might be problematic in the post-HSCT population 17 . Typhlitis due to Clostridium septicum infection is characterized by inflammation of the caecum and presents with fever and right lower quadrant abdominal pain 2-4 weeks following cytotoxic chemotherapy or conditioning chemotherapy, at which point neutrophil counts are at their nadir 131 . In contrast to acute GVHD, typhlitis most often presents before bone marrow engraftment. If typhlitis is suspected, imaging must be performed and might reveal bowel wall thickening and mucosal enhancement, predominantly in the ileocaecal region 132 . If detected, empirical therapy with broad-spectrum antibiotics should be initiated and surgical consultation should be considered 132 . Initial antibiotic coverage must be active against C. septicum, Pseudomonas aeruginosa and other colonic microbiota that might translocate through a bowel wall that has been compromised by clostridial toxins 133 . Typical empirical regimens include piperacillintazobactam monotherapy, cefepime in combination with metronidazole, or ceftazidime with metronidazole.
Cord colitis syndrome (CCS) is a proposed clinical entity that presents as a persistent diarrhoeal illness in ~10% of patients who receive cord blood transplantation and causes a granulomatous inflammation of the upper and lower gastrointestinal tract 134 . CCS is considered a diagnosis of exclusion once acute GVHD and demonstrable infectious aetiologies have been ruled out 134 . Although the syndrome is responsive to anti biotics, a causative pathogen has not been definitively identified 135 . CCS most often presents several months following cord blood transplantation with watery diarrhoea and fever. Colonoscopy reveals erythematous mucosa with or without ulceration, and biopsy demonstrates chronic active colitis, frequently with associated granulomas 136 . This clinical entity remains controversial, as studies have suggested that CCS is not a histopathologically distinct disease from acute GVHD 137, 138 .
Management
Once alternative causes of post-HSCT gastro intestinal symptoms have been thoroughly considered and excluded and a diagnosis of acute GVHD has been established, prompt treatment should be initiated. Following HSCT, patients should receive GVHD prophylaxis, and those who later develop GVHD should be assessed for the adequacy of their prophylactic regimen, with adjustment as required. First-line treatment regimens consist of systemic and/or oral non-absorbable corticosteroids. Unfortunately, non-response to first-line treatment is common, and data regarding the effectiveness of various second-line treatment modalities is limited. Supportive care throughout the duration of illness is of critical importance and focuses on symptomatic management 139 .
Prophylaxis of acute GVHD. Prophylaxis of acute GVHD is based upon suppression of the engrafted cytotoxic T cell-mediated immune response. Factors considered in selecting a prophylactic regimen include 
Unrelated donor HSCT
A type of allogeneic transplant in which the donor is not related to the patient.
HLA-mismatched transplantation
A type of allogeneic transplantation in which the HLA typing of the donor and recipient are not identical.
the underlying malignancy, the chemotherapy regimen used for conditioning, the extent of HLA discordance between the donor and recipient, the susceptibility of the patient to infection and the desire of the physician to balance graft immunosuppression with the desired graft-versus-tumour effect 140 . A common prophylactic regimen consists of a course of methotrexate combined with a prolonged tapering dose of a calcineurin inhibitor 141, 142 . Among patients who receive less aggressive conditioning regimens, methotrexate might be replaced with MMF or EC-MPS (to avoid methotrexate-related toxicity) 143, 144 . Patients who receive an unrelated donor HSCT or an HLA-mismatched transplantation are at greater risk of developing acute GVHD, and such patients can undergo T cell depletion or post-transplantation treatment with cyclophosphamide, which might reduce the incidence of acute GVHD 145, 146 .
Treatment of acute GVHD. The initial step in the management of acute GVHD is the evaluation of the patient's prophylactic regimen 147 . Among patients who discontinue prophylaxis, the prophylactic regimen can be restarted; in patients still receiving prophylaxis, drug levels can be optimized via dosage increase if serum drug levels are low.
The mainstay first-line treatment strategy for gastrointestinal acute GVHD comprises corticosteroids 147 . A common starting regimen with systemic corticosteroids is prednisone or methylprednisolone at doses of 1-2 mg/kg per day in divided doses (typically every 12 hours). For patients with less severe disease (grade II), initial treatment with a lower dose of prednisone (1 mg/kg/day) has also been shown to be effective 148 . Conversely, corticosteroid doses >2 mg/kg/day do not provide additional therapeutic benefit across grades of severity 149 . At any grade of severity, concomitant use of oral non-absorbable corticosteroids, such as budesonide or beclomethasone, might improve response rates and also helps to moderate the dose of systemic corticosteroid therapy 150, 151 . For patients with mild to moderate disease severity, monotherapy with oral beclomethasone dipropionate is a reasonable initial therapeutic approach 152 . In patients with mild to moderate colonic acute GVHD, we have also prescribed budesonide MMX (Cosmo Pharmaceuticals NV), an oral formulation that uses a multi-matrix system to extend budesonide release throughout the colon, which has been studied in patients with ulcerative colitis 153 . Corticosteroids are generally continued for several weeks and slowly tapered to prevent relapse 154 . Patients who demonstrate disease progression at day 5 of treatment, or no improvement by day 7, are deemed steroid-refractory and are likely to require second-line agents 147, 154 . A substantial proportion of patients with acute GVHD fail to respond to first-line corticosteroids. In a study from 2015, 31% of standard-risk patients and 57% of high-risk patients were steroid-refractory. 111 There are also data showing that patients with lower gastrointestinal involvement are at particularly high risk of nonresponse 155 . Unfortunately, there is an insuffi cient amount of quality data to guide the management of patients who fail to respond to corticosteroids, and their outcomes are gener ally poor 139 . Several second-line thera pies are currently available to treat patients who are steroidrefractory, including lymphocyte-depleting agents, cell cycle inhibitors, antimetabolites, TNF antago nists, inhibitors of leukocyte trafficking, anti bodies directed against various interleukins, extra corporeal photo pheresis and others 139 . A detailed discussion of second-line therapies is beyond the scope of this article, and we direct the reader to a relevant review 139 .
Supportive care and management of gastrointestinal complications in acute GVHD. In addition to immunosuppressive therapies, treatment of acute GVHD inclu des symptomatic management of nausea, vomiting, mucositis, dysphagia, diarrhoea, abdominal pain, bleeding and malnutrition. Patients with severe disease might be placed on bowel rest ('nil per os' (NPO)) to prevent exacerbation . Low-dose corticosteroids are also effectively used as prophylactics 157 . Other agents for symptomatic management include phenothiazines, metoclopramide, lorazepam, haloperidol and dronabinol. Aprepitant, a neurokinin 1 receptor antagonist, is effective for symptomatic management; however, it should be noted that aprepitant interacts with various immunosuppressants, as it is a substrate and a moderate inhibitor of human cytochrome P450 3A4, which has a crucial role in the hepatic metabolism of calcineurin inhibitors 158 . Oropharyngeal mucositis, dysphagia and odynophagia can lead to anorexia and malnutrition; supportive measures include the use of topical anaesthetics. Viscous lidocaine is included in formulations known as 'magic mouthwashes' , which contain components such as antibiotics, antifungals, antihistamines, steroids and coating agents. Saline solution has been shown to be as effective as a 'magic mouthwash' for analgesia and healing of mucositis 159 . In addition, antiseptic mouth rinses such as chlorhexidine gluconate aid in the prophylaxis of oral superinfection but might also exacerbate symptoms of mucositis. For symptoms of oesophagitis, the mainstay of therapy is PPIs 158 . Although coating agents such as sucralfate are often used in conjunction with PPIs, there is little evidence to support their efficacy, and there is concern that they might decrease the absorption of other medications; thus, they are not recommended by expert guidelines 160 . Chronic abdominal pain related to acute GVHD is difficult to treat. The pain is attributed to inflammation, oedema, increased mucosal friability and ileus 161 . The use of NSAIDs and paracetamol might be limi ted by bleeding and hepatotoxicity risks, respectively. Therefore, opioid analgesics (morphine, hydro morphone and so on) are often necessary. Opioids should be used with caution in patients with acute GVHD, as they can further impair neuromuscular activity, hinder gut propulsion and inadvertently exacerbate pain 162 . In an effort to combat these adverse effects, the μ-opioid receptor antagonist methylnaltrexone might be used pre-emptively 163 . Alternatively, buprenorphine, a μ-opioid receptor partial agonist and a κ-opioid receptor and δ-opioid receptor antagonist, might offer analgesia with less frequent and less severe adverse gastrointestinal effects 164 . Finally, non-narcotic analgesics such as GABA analogues, serotonin-noradrenaline reuptake inhibitors and tricyclic anti depressants might have a role as adjuncts for neuropathic gastrointestinal pain 162 . The management of diarrhoea is one of the greatest challenges in acute GVHD (TABLE 4) . Anti-diarrhoeal agents should be initiated after infection is excluded, as decreasing stool output might delay clearance of pathogenic bacteria and their associated toxins, thus lengthening the disease course 165 . Loperamide is the initial anti-diarrhoeal agent of choice, but if ineffective, octreo tide or tincture of opium might be used and titrated to elicit the desired response 166 . The combin ation of atropine and diphenoxylate is a commonly used antimotility agent; however, it must be used with caution, as it can provoke ileus (pseudo-obstruction) 167 . A trial of pancreatic enzyme supplementation might also be considered, as there is evidence that acute GVHD can cause pancreatic insufficiency 168, 169 . The addition of a bile-acid-binding resin (known as a bile acid sequestrant) might also be beneficial 168, 169 ; however, such agents should be used judiciously, as they can interfere with the absorption of other medications. Stool output must be measured diligently, and anti-motility agents should be tapered as soon as diarrhoea begins to subside to prevent the development of ileus 59 . Patients who receive HSCT commonly develop macronutrient and micronutrient deficiencies secondary to profound gastrointestinal symptoms, systemic inflammation, protein-losing enteropathy and med ication toxicity 59 . Malnutrition and hypoalbuminaemia are well-established factors associated with poor prognosis and thus must be addressed 60 . Patients should receive formal nutritional evaluations to determine their need for supplemental enteral and/or parenteral nutrition. Oral feeding is preferable in order to maintain both intestinal function and the mucosal barrier and concomi tantly avoids the potential complications of total parenteral nutrition (TPN) 170 . However, TPN might be the only available option for patients with severe diarrhoea and an inability to tolerate sufficient oral intake. If TPN is initiated, an early re-introduction of oral intake leads to improved nutritional outcomes 171 .
Gastrointestinal bleeding secondary to acute GVHD typically results from diffuse mucosal oozing of blood and is rarely amenable to endoscopic intervention 158 . Nonetheless, endoscopic evaluation is warranted to exclude lesions that might be treatable. The mainstay of therapy for acute GVHD-related haemorrhage include supportive therapy to correct thrombocytopenia and coagulopathy, acid suppression and treatment of GVHD 158 . Continuous infusion of octreotide has been studied for the treatment of GVHD-related gastrointestinal bleeding, but its efficacy is lost when the drug is discontinued 172 . In the setting of ongoing bleeding that cannot be managed with conservative approaches, cases of successful arterial embolization have been reported 173 . Another technique is intra-arterial platelet transfusion 174 . Surgical management is typically not feasible, given the diffuse nature of the disease and the high surgical risk of these patients.
Conclusions
Although the pathophysiology of acute GVHD remains to be fully elucidated, acute GVHD seems to be largely a result of dysregulated cell-mediated immunity, which prompts an aggressive cytotoxic response by donor lympho cytes. Emerging evidence suggests that imbalances in the gut microbiota probably also have an important role in the development of acute GVHD of the gastrointestinal tract. Although serological markers, radiology and endoscopy all have important roles in the evaluation of patients with gastrointestinal acute GVHD, the diagnosis ultimately depends on identification of classical clinical features and the exclusion of alternative diagnoses. Given the nonspecific presentation of acute GVHD, a broad differential diagnosis should be considered and should include the effects of myeloablative conditioning regimens, ongoing immunosuppressive prophylaxis, viral infection and bacterial infection (particularly with C. difficile). Endoscopic findings might vary broadly and reflect the phases of progressive mucosal inflammation. Although the diagnosis of acute GVHD should be confirmed using tissue biopsy when possible, the diagnosis is ultimately made on the basis of clinical findings, and biopsies should not delay the management of the disease in patients who present with classic clinical features. Biopsy samples from the distal colon yield the highest sensitivities for detecting acute GVHD and should be obtained from multiple sites given the typically patchy, diffuse nature of the disease. The histological grade of biopsy specimens has not been shown to correlate with clinical manifestations of disease and is not predictive of treatment response, morbidity or mortality. Several novel biomarkers have been identified that might help anticipate the risk of developing acute GVHD, diagnose the disease at earlier stages, estimate the prognosis and predict response to treatment; however, to date, none have been integrated into routine clinical practice. First-line treatment regimens for acute GVHD consist of corticosteroids; higher dose corticosteroids are not superior to more moderate dosages, and the use of oral, non-absorbable corticosteroids can help to further reduce systemic dose requirements. Failure to respond to first-line treatment is common and should prompt the re-evaluation of the patient for possible alternative or concomitant diagnoses. Although a number of second-line treatments are available, outcomes among corticosteroid non-responders remains dismal.
Accordingly, acute GVHD of the gastrointestinal tract is a major challenge in the clinical management of patients with haematological malignancies who receive HSCT. In spite of ongoing advances, GVHD remains a common occurrence at centres that perform HSCT. Severe gastrointestinal acute GVHD has a poor prognosis and can be catastrophic if it is not expediently diagnosed and treated. Although the diagnosis and treatment of acute GVHD generally falls within the realm of the haematologist and oncologist, the involvement of the gut necessitates the consultation of a gastroenterologist. Gastroenterologists have a central role in both diagnosis and risk stratification of acute GVHD of the gut via endoscopy and tissue biopsy. They also manage gastro intestinal complications, including gastro intestinal bleeds, and can guide aspects of supportive care such as treatment of diarrhoea and malnutrition. A collaborative, multidisciplinary approach involving haematologists, gastroenterologists and pathologists is most likely to lead to improved outcomes in the vulnerable population of patients with acute GVHD of the gut.
